Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.


TSX:BCT - Post by User

Post by LondonInveston Mar 25, 2022 7:39am
309 Views
Post# 34544324

Potential for this company - 10x ($100+/share)

Potential for this company - 10x ($100+/share)


I have bought BCTX aggressively because it is a very undervalued company for it's potential value in its research.  I have been trying to calculate what potential value is if their tech continues to be confirmed and it can be applied to lung, prostate, renal and other cancers in addition to breast cancer. 

A 10x increase in price to a market cap of $1.5 bn seems too cheap.  A 50x increase gets to $7.5 billion.  This seems the right value and where Moderna was pre-COVID. 

Thinking out loud.  They have enough cash on hand to get 2-3 years research.  This company will not be public and/or it will have a partnership before that time.  Based on appreciation potenial above it would get to a share price around $90-$400 per share.  I really don't think a valuation over $100 is unreasonable and multiples is possible if results continue to come in showing massive application and potential BCTX research has. 

Happy to hear other thoughts on this and other biotech comparisons that could be made.

<< Previous
Bullboard Posts
Next >>